Agoracom Blog Home

Posts Tagged ‘energy drink’

Tetra Natural Health $ Will Deliver 20 containers of #Hemp Energy Drink to Meet Consumer Demand $AERO $CBDS $CGRW $GBLX

Posted by AGORACOM-JC at 8:28 AM on Monday, December 3rd, 2018

Logo tetrabiopharma rgb web

  • Announces the delivery of twenty containers, more than 1.7 million cans of its product Hemp Energy Drink,
    • the first hemp energy drink in Canada, to meet growing demand in Canada and to make Hemp Energy Drink available across all regions of the country.

ORLEANS, Ontario, Dec. 03, 2018 — Tetra Natural Heath, a subsidiary of Tetra Bio-Pharma (TSX VENTURE: TBP) (OTCQB: TBPMF), announces the delivery of twenty containers, more than 1.7 million cans of its product Hemp Energy Drink, the first hemp energy drink in Canada, to meet growing demand in Canada and to make Hemp Energy Drink available across all regions of the country.

Hemp Energy Drink available in 3 flavours: Classic, Mango and Raspberry

Canadian consumers appreciate the qualities of Hemp Energy Drink ( that contains fewer calories and more natural ingredients than other energy drinks, and the product will be available soon everywhere in Canada in three flavors: classic, mango and raspberry.

“We are very pleased with the consumer interest for the Hemp Energy Drink since its launch. Through the agreements we have with our distribution partners, their drive and the strategy we are implementing, Canadians will soon be able to appreciate the three flavors of our cool, fresh, light, natural and 100% legal beverage,” said Richard Giguère, CEO of Tetra Natural Health.

“This 20-container delivery combined with the deployment of our distribution strategy represents an important step in our market development plan for this product over the next year. Thanks to the characteristics of our energy drink and its nutritional elements, we are confident that the Hemp Energy Drink will generate a continued enthusiasm among consumers across Canada,” added Richard Giguère.

Guy Chamberland, President and CEO of Tetra Bio-Pharma stated, “With its Hemp Energy Drink business, Tetra Natural Health will allow the corporation to achieve significant orders and sales over the coming year.  These orders demonstrate that the new team has established a viable natural health and wellness product business that will translate into significant revenues for the coming fiscal year, starting in Q1 2019.”

About Tetra Natural Health
Tetra Natural Health inc. is a subsidiary of Tetra Bio-Pharma inc. that focuses on identification, development and marketing of hemp or cannabis-based natural health products, or cannabinoids-based products authorized for sale by Health Canada.

About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid- based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit:

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including this trial, the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions, the success of various product launches including the one discussed in this release, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For more information, please contact:
Richard Giguère
Tetra Natural Health
T 348-899-7575 ext.210
[email protected]

Media Contact
Daniel Granger
ACJ Communication
T. 514 840-7990
M. 514 232 1556
[email protected]

Charlotte Blanche
T. 514 840-1235 poste 7772
M. 514 914-0593
[email protected]

A photo accompanying this announcement is available at